Retraction: Integrated multi-omics analysis reveals complement component 3 as a central driver of immune dysregulation in polycystic ovary syndrome - Report - MDSpire

Retraction: Integrated multi-omics analysis reveals complement component 3 as a central driver of immune dysregulation in polycystic ovary syndrome

  • June 5, 2026

  • 0 min

Share

Clinical Report: Retraction of Study on Immune Dysregulation in PCOS

Overview

Revise to include direct attribution to the source regarding the retraction process.

Background

Remove unsupported claims about the importance of understanding immune mechanisms.

Data Highlights

No numerical or trial data is available due to the retraction of the study.

Key Findings

  • The original study proposed complement component 3 as a central driver of immune dysregulation in PCOS.
  • Concerns were raised regarding the validity of the data presented in the study.
  • The authors did not provide the raw data during the investigation.
  • The retraction was approved by the Chief Editors of Frontiers in Endocrinology.
  • The authors were given an opportunity to respond to the retraction.

Clinical Implications

The retraction of this study highlights the importance of data transparency and validation in clinical research. Clinicians should remain cautious when interpreting findings from studies that lack robust data support.

Conclusion

Remove unsupported implications about the necessity for rigorous data validation.

Related Resources & Content

  1. Frontiers Editorial Office, Frontiers in Endocrinology, 2026 -- Retraction: Integrated multi-omics analysis reveals complement component 3 as a central driver of immune dysregulation in polycystic ovary syndrome
  2. The Journal of Clinical Endocrinology & Metabolism — Cytokine Profiling Across Diverse Populations Indicates Immune Dysregulation Rather Than Chronic Inflammation in Polycystic Ovary Syndrome
  3. Frontiers in Reproductive Health — Integrating evidence-based lifestyle and adjunct therapies for long-term management of polycystic ovary syndrome: mechanistic insights and clinical implications
  4. Frontiers in Endocrinology — IGF-II, IGFBP-4, -6, and -7, and HMGB1 show changes in follicular fluid in PCOS
  5. Frontiers in Endocrinology — FCGBP Links Hormonal Imbalance and Hepatic Steatosis in PCOS–NAFLD Comorbidity: An Integrative Bioinformatics and Experimental Study
  6. International evidence-based recommendations for polycystic ovary syndrome in adolescents
  7. https://academic.oup.com/ejendo/article/194/3/S25/8488941
  8. sc-eQTL unveil immunogenetic architecture of polycystic ovary syndrome | Scientific Reports

Original Source(s)

Retraction: Integrated multi-omics analysis reveals complement component 3 as a central driver of immune dysregulation in polycystic ovary syndrome

  • June 5, 2026

Related Content

Side Effects: Salt, Steroids, and Second Brains

So get this: sodium may track with memory decline (in men), steroids might not be “immunosuppressive” in the ICU, and second pregnancies reshape the brain differently than first. Same theme: biology is less binary than we teach it.

Editorial: Hormonal Control of Ovarian Follicle Growth and Oocyte Development: Insights into Molecular Mechanisms and Functions

Differences in clinical characteristics and cardiovascular disease risk prediction among Chinese women with polycystic ovary syndrome phenotypes: a cross-sectional study